Design, synthesis, and anti-prostate cancer activity evaluation of novel thieno[2,3-b]pyridine derivatives as potential BLM helicase inhibitors.

Wei Tu Ningning Zan Xinyu Liu Gang Yu Xiaoping Zeng Yafang Zhou Jia Yu Xue Meng Kun Liu Xiaolin Peng Sha Cheng Bi-Xue Xu Guangcan Xu

Jul 2026 · Molecular diversity · 0 citations · 55 references

Medicine

TL;DR

Nine novel thieno[2,3-b]pyridine derivatives were rationally designed and synthesized based on a versatile key intermediate, representing a promising lead compound for the development of novel BLM-targeted anti-prostate cancer agents.

DOI PubMed Semantic Scholar

View source

Similar papers

Aug 2026

Design, synthesis, antitumor estimation, and molecular docking of new imidazothiazolediones as potential dual EGFR and IDO1 inhibitors and apoptosis stimulators.

Findings highlight compound 5d as a promising lead candidate for further optimization and cellular mechanistic validation in anti-cancer drug discovery.

M. Sarg, Fatma G. Abdulrahman, Yasmin S. Sheta et al. · Bioorganic & Medicinal Chemi... · 0 citations

Jul 2026

Design, synthesis and evaluation of benzo[4,5]thiazolo[3,2-a]pyrimidin-4-one derivatives as novel MTA cooperative PRMT5 inhibitors for the treatment of MTAP-deleted cancers.

Compound 9u exhibited significant antiproliferative activity in MTAP-deleted HCT116 cancer cells, with an IC50 value of 13 nM, exhibiting 70-fold selectivity over MTAP wild type HCT116 cells, and 9u displayed robust efficacy across diverse MTAP-deleted cancer cell lines, achieving IC50 values of <1.5-51 nM.

Bing Liu, Shao-Yan Li, Hui Shi et al. · Bioorganic chemistry (Print) · 0 citations

Open access Jul 2026

Structural design and cytotoxic profiling of a novel 1,3,4-thiadiazole derivative targeting MCF-7 and HCT-116 cell lines: synthesis, cytotoxicity, and in silico study

In silico investigations, including molecular docking, molecular dynamics simulations, and MM/GBSA analysis, revealed stable binding of the synthesized compound within the VEGFR2 active site, supported by favorable binding free energy and key ligand–residue interactions.

Mostafa Sayed, Ehdaa Mohammed, Doha H. Aboubaker et al. · RSC Advances · 0 citations

Open access Aug 2026

Novel benzofuran-furan-pyrano[2,3-c]pyrazole hybrids as potential anticancer agents: design, synthesis, in silico profiling, and multi-mechanistic biological evaluation

It is demonstrated that benzofuran-furan-pyrano[2,3-c]pyrazole hybrids possess promising multifaceted in vitro anticancer activity by inhibiting cancer cell proliferation, migration, invasion, and clonogenicity while inducing ROS-mediated mitochondrial apoptosis, highlighting these hybrid scaffolds as attractive candid...

E. Hutanu, Bassam A. Najri, A. Abdelsalam et al. · RSC Advances · 0 citations

Aug 2026

Design, synthesis, anticancer evaluation, and molecular dynamics-based computational investigation of novel pyrimidine-benzothiazole/phenyl hybrid-based VEGFR-2-targeted derivatives with antioxidant, DNA nicking, DNA interaction, and cytotoxicity studies.

Overall, K12 emerged as the most promising lead compound, combining potent antiproliferative activity, high selectivity, efficient DNA-binding characteristics, and robust computational performance, highlighting its potential for further development as a novel anticancer agent.

Karan Kamle, Shreyansh R. Mevada, Reena Hirani et al. · Bioorganic chemistry (Print) · 0 citations

Open access Aug 2026

Novel benzofuran-1,3,4-thiadiazole aryl urea hybrids as dual VEGFR-2/BRAF inhibitors: anticancer activity, apoptosis induction, and molecular modeling studies.

A novel series of benzofuran-based aryl urea derivatives incorporating a 1,3,4-thiadiazole linker were designed as dual VEGFR-2/BRAFWT inhibitors using sorafenib as a pharmacophoric template, with compound 7j emerging as the most active analogue.

Marwa I. Serag, Mohamed R. Elnagar, Wafaa A. Ewes et al. · Bioorganic & Medicinal Chemi... · 1 citation